All In Biotech

Drug Trial Radar · NCT06821698

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

An Open-label Study to Determine the Effect of Oral Doses of KP-001 on Rosuvastatin and Caffeine PK After a Single Oral Administration and to Determine the Effect of Fluvoxamine on KP-001 PK After a Single Oral Administration in Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Feb 13, 2025

Primary completion

May 20, 2025

Study completion May 20, 2025

Sponsor

Lead sponsor
Kaken PharmaceuticalIndustry
Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1 will evaluate the effects of KP-001 as an inhibitor of BCRP on the PK of rosuvastatin. In the Treatment Period 1, a single dose of rosuvastatin will be administered. In the Treatment Period 2, KP-001 will be administered once daily for 7 days and a single dose of rosuvastatin will be administered. Blood PK assessments of rosuvastatin will be performed until 48 hours postdose in each Treatment Period. Part 2 will evaluate the effects of KP-001 as an inducer and inhibitor of CYP1A2 on the PK of caffeine. A single dose of caffeine will be administered in the Treatment Period 1. KP-001 will be administered once daily for 10 days and a single dose of caffeine will be administered in the Treatment Period 2. Blood PK assessments of caffeine will be performed until 24 hours postdose in each Treatment Period. Part 3 will evaluate the effects of fluvoxamine as an inhibitor of CYP1A2 on the PK of KP-001. A single dose of KP-001 will be administered in the Treatment Period 1. Fluvoxamine will be administered as a single dose on the first day and then twice daily for 5 days and a single dose of KP-001 will be administered in the Treatment Period 2. Blood PK assessments of KP-001 will be performed until 48 hours postdose in each Treatment Period.

Conditions

  • Healty Volunteers

Interventions

  • KP-001Drug

    KP-001 100 mg dry syrup

  • Rosuvastatin calcium10mgDrug

    A oral dose of 10 mg tablet

  • Caffeine citrateDrug

    100 mg oral solution

  • FluvoxamineDrug

    50 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters of rosuvastatin in plasma: AUCinfTime frame: 48hour
  2. PK parameters of rosuvastatin in plasma: CmaxTime frame: 48hour
  3. PK parameters of caffeine in plasma: AUCinfTime frame: 24hour
  4. PK parameters of caffeine in plasma: CmaxTime frame: 24hour
  5. PK parameters of KP-001 in plasma: AUCinfTime frame: 48hour
  6. PK parameters of KP-001 in plasma: CmaxTime frame: 48hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International Early Phase Clinical Unit

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.